期刊文献+

防耐药突变体选择浓度和耐药突变选择窗理论的研究进展 被引量:8

Research of mutant prevention concentration and mutant selection window
下载PDF
导出
摘要 目的:阐述防耐药突变体选择浓度和耐药突变选择窗理论的最新研究进展。方法:查阅近年来国内外相关文献资料进行整理归纳。结果与结论:体外MPC测定、体外药效学研究、动物感染模型、人体内研究验证了MSW理论,防耐药突变体选择浓度和耐药突变选择窗理论为评价细菌耐药新的重要指标。 Objective: To review the recent research of mutant prevention concentration (MPC) and mutant selection window (MSW). Methods: Pertinent literature about MPC and MSW was reviewed. Results and Conclusion: MPC and MSW theory was verified by MPC determination in vitro, pharmacodynamics in vitro, animal infectious model and studies in vivo. MPC and MSW theory is a new strategy to evaluate the bacterial resistance.
出处 《中国药物应用与监测》 CAS 2008年第4期39-41,共3页 Chinese Journal of Drug Application and Monitoring
关键词 防耐药突变体选择浓度 耐药突变选择窗 耐药突变株 Mutant prevention concentration Mutant selection window Resistant mutants
  • 相关文献

参考文献13

  • 1[1]Zhao X,Drlica K.Restricting the selection of antibiotic-resistant mutants:a general strategy derived from fluoroquinolones studies[J].Clin Infect Dis,2001,33(Suppl):S147-S156.
  • 2[2]Drlica K.A strategy for fighting antibiotic resistance[J].ASM news,2001,67(1):27-33.
  • 3[3]Ddiea K.The mutant selection concentration and antimicrebial resistance[J].J Antimicrob Chemother,2003,52(1):11-17.
  • 4[4]Dong Y,Zhan X,Donmgal AJ,et al.Effect of fluoroquinolone concentration on selection of resistant mutants of mycobacteriumbovis BCG and staphylococcus aureus[J].Antimicrob Agents Chemother,1999,43(7):1756-1758.
  • 5[5]Blondeau JM,Zhao X,Hansen J,et al.Mutant prevention concentration of fluoroquinolones for clinical isolates of streptococcus pneumoniae[J].Antimicrob Agents Chemother,2001,45(2):433-438.
  • 6[6]Hansen G,Metzler K,Drlica K,et al.Mutant prevention concentration for gemifloxacin with clinical isolates of streptococcus pneumoniae[J].Antimicro Agents Chemother,2003,47(1):440-441.
  • 7[7]Firsov AA,Vostrov SN,Lubenkob IY,et al.In vitro pharmacedynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against staphylococcus aureus[J].Antimicrob Agents Chemother,2003,47(5):1604-1613.
  • 8[8]Zinner SH,Lubenko IY,Gilbea D,et al.Emergence of resistant streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window:related changes in susceptibility,resistance frequency and bacterial killin[J].J Antimicrob Chemother,2003,52(4):616-622.
  • 9[9]Firsov AA,Vostrov SN,Lubenko IY,et al.Prevention of the selection of resistant staphylococcus aureus by moxifloxacin plus doxyeycline in an in vitro dynamic model:an additive effect of the combination[J].Int J Antimicrob Agents,2004,23(5):451-456.
  • 10[10]Creisier D,Etienne M,Bergoin E,et al.Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy[J].Antimicrob Agents Chemother,2004,48(5):1699-1707.

同被引文献146

引证文献8

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部